CLINICAL STUDIES ON DL-8280 IN THE RESPIRATORY TRACT INFECTION

Clinical effects and adverse effects of DL-8280, a new antimicrobial agent, were studied in 36 patients with respiratory tract infections receiving orally 100 mg to 300 mg b. i. d. or t. i. d. Among them, 35 cases were lower respiratory tract infections, one case was lung abscess. The clinical effec...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 32; no. Supplement1; pp. 263 - 271
Main Authors NAKAMORI, YOSHITAKA, YOSHIMURA, KUNIHIKO, NAKATANI, TATSUO, CHONABAYASHI, NAOHIKO, TACHIBANA, AKIO, NAKATA, KOICHIRO, TANIMOTO, HIROICHI, NOZAWA, KYOKO
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1984
Online AccessGet full text

Cover

More Information
Summary:Clinical effects and adverse effects of DL-8280, a new antimicrobial agent, were studied in 36 patients with respiratory tract infections receiving orally 100 mg to 300 mg b. i. d. or t. i. d. Among them, 35 cases were lower respiratory tract infections, one case was lung abscess. The clinical effects were excellent in 2 cases, good in 15 cases, fair in 6 cases and poor in 12 cases, and one case was not evaluated because of adverse effect. The efficacy rate was 49%. As for adverse effects, glossitis, diarrhea and stomach sickness were observed in 1 case, and appetite loss was observed in 2 cases.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.32.Supplement1_263